MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission

AIDS

Volumn 24, Issue 6, 2010, Pages 833-840

  Bellusci, Carolina P ^a   Rocco, Carlos A ^a   Aulicino, Paula C ^a   Mecikovsky, Debora ^b   Bologna, Rosa ^b   Sen, Luisa ^a   Mangano, Andrea ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

C1236T; C3435T; Disease progression; HIV 1; MDR1; P glycoprotein; Pediatric AIDS; Single nucleotide polymorphism; Vertical transmissio

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ARTICLE; BLOOD DONOR; CHILD; CONTROLLED STUDY; DISEASE COURSE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIRUS TRANSMISSION;

ALLELES; ARGENTINA; DISEASE PROGRESSION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; P-GLYCOPROTEIN; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77949543949     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328336abfc     Document Type: Article

References (49)

1. de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189:551-557.
2. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29:607-649.
3. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268:6077-6080.
4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267:24248-24252.
5. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M,Jeang KT, Ambudkar SV, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-3601.
6. Cianfriglia M, Dupuis ML, Molinari A, Verdoliva A, Costi R, Galluzzo CM, et al. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 2007; 4:17.
7. Siegsmund M, Brinkmann U, Scháffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13:1847-1854.
8. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70:949-958.
9. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmo-hamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 2005; 59:365-370.
10. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289-294.
11. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28:655-660.
12. Ford J, Hoggard PG, Owen A, Khoo SH, Back DJ. A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods 2003; 274:129-137.
13. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
14. Camus M, Deloménie C, Didier N, Faye A, Gil S, Dauge MC, et al. Increased expression of MDR1 mRNAs and P-glycopro-tein in placentas from HIV-1 infected women. Placenta 2006; 27:699-706.
15. Fojo A, Lebo R, Shimizu N, Chin JE, Roninson IB, Merlino GT, et al. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet 1986; 12:415-420.
16. Owen A, Chandler B, Back DJ. The implications of P-glyco-protein in HIV: friend or foe? Fundam Clin Pharmacol 2005; 19:283-296.
17. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794:860-871.
18. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
19. Owen A, Chandler B, Bray PG, Ward SA, Hart CA, Back DJ, et al. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol 2004; 78:12022-12029.
20. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
21. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005; 19:371-380.
22. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 2003; 34:295-298.
23. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003; 17:1696-1698.
24. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, et al. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immu-nological response in treatment näive HIV-positive patients. Ann Clin Microbiol Antimicrob 2005; 4:3.
25. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
26. Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Nakamura T, Yamada H, et al. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther 2004; 9:929-935.
27. Bleiber G, May M, Suarez C, Martinez R, Marzolini C, Egger M, et al. Swiss HIV Cohort Study. MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. J Infect Dis 2004; 189:583-586.
28. Lee CG, Ramachandra M, Jeang KT, Martin MA, Pastan I, Gottesman MM. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 2000; 14:516-522.
29. Speck RR, Yu XF, Hildreth J, Flexner C. Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002; 186:332-340.
30. Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, et al. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J Acquir Immune Defic Syndr 2003; 34:119-126.
31. Kedmi M, Maayan S, Cohen SB, Hauzi M, Rund D. MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease. AIDS Patient Care STDS 2007; 21:653-658.
32. Ifergan I, Bernard NF, Bruneau J, Alary M, Tsoukas CM, Roger M. Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS 2002; 16:2340-2342.
33. US Center for Disease Control and Prevention classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mort Wkly Rep 1994; 43:1-10.
34. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sulli-van MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
35. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174; Erratum in Clin Pharmacol Ther 2004; 75:124.
36. Mangano A, Kopka J, Batalla M, Bologna R, Sen L. Protective effect of CCR2-64I and not of CCR5-delta32 and SDF1-3 A in pediatric HIV-1 infection. J Acquir Immune Defic Syndr 2000; 23:52-57.
37. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10:1100-1120.
38. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12:529-534.
39. Bernal ML, Sinues B, Fanlo A, Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit 2003; 25:107-111.
40. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmaco-genetics 2001; 11:217-221.
41. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 2006; 21:126-132.
42. Comings DE, MacMurray JP. Molecular heterosis: a review. Mol Genet Metab 2000; 71:19-31.
43. Hellemann D, Larsson A, Madsen HO, Bonde J, Jarløv JO, Wiis J, et al. Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients. Hum Mol Genet 2007; 16:3071-3080.
44. Hendrickson SL, Jacobson LP, Nelson GW, Phair JP, Lauten-berger J, Johnson RC, et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J Acquir Immune Defic Syndr 2008; 48:263-271.
45. Misrahi M, Teglas JP, N'Go N, Burgard M, Mayaux MJ, Rouzioux C, et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. JAMA 1998; 279:277-280.
46. Tresoldi E, Romiti ML, Boniotto M, Crovella S, Salvatori F, Palomba E, et al., European Shared Cost Project Group; Italian Register for HIV Infection in Children. Prognostic value of the stromal cell-derived factor 1 3'A mutation in pediatric human immunodeficiency virus type 1 infection. J Infect Dis 2002; 185:696-700.
47. Llano M, Kelly T, Vanegas M, Peretz M, Peterson TE, Simari RD, et al. Blockade of human immunodeficiency virus type 1 expression by caveolin-1. J Virol 2002; 76:9152-9164.
48. Cai C, Chen J. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int J Cancer 2004; 111:522-529.
49. Ronaldson PT, Bendayan M, Gingras D, Piquette-Miller M, Bendayan R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J Neurochem 2004; 89:788-800.